(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

8 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

    Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  M2e1VmNmdGxiVnnhZoltcXS7IFHzd4F6 NG[1N|IzPTBxNUCwM|ExODBibl2= NGrKelgzPC92OD:3NkBp NILFV5BFVVOR Moi0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MmTDNlY4ODd6OEG=
BCPAP M3fheGNmdGxiVnnhZoltcXS7IFHzd4F6 MkeyNlUxNzVyMD:xNFAxKG6P M4fITVI1NzR6L{eyJIg> MlKxSG1UVw>? MWnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NGjVS2kzPjdyN{i4NS=>
K1  Mn7kR4VtdCCFeXPs[UBCe3OjeR?= MoLINlUxNzVyMD:xNFAxKG6P MYC3NkBp MVvEUXNQ M1HmdIFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= MVqyOlcxPzh6MR?=
BCPAP NIq3fWxE\WyuIFP5Z4xmKEG|c3H5 MWCyOVAwPTByL{GwNFAhdk1? NWDkXpJ4PzJiaB?= NV\0c253TE2VTx?= MojFZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn MU[yOlcxPzh6MR?=
Hep3B MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXPfpAxNTFyIN88US=> MlvjOUBl MXzEUXNQ MYTJR|UxRTBwMEig{txO MUCyOlU4PTF4Nx?=
HCCLM3 NInvRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;CNE0yOCEQvF2= M1HTRVUh\A>? NHe2TJdFVVOR M2L1Z2lEPTB;MD6xOEDPxE1? NFnUcWczPjV5NUG2Oy=>
HuH7 NXzmXXdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX6NE0yOCEQvF2= M3zrblUh\A>? M{CzZ2ROW09? NG\hOo1KSzVyPUCuNlEh|ryP NGe0fYwzPjV5NUG2Oy=>
HepG2 NGnNOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHkWm8xNTFyIN88US=> NXPNRXFqPSCm MnXjSG1UVw>? M3LjU2lEPTB;MD6zOEDPxE1? NIDLZY8zPjV5NUG2Oy=>
SMMC7721 NWPwRoJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO5N4tFOC1zMDFOwG0> NHjC[no2KGR? M4jTcWROW09? NXPZdGV1UUN3ME2wMlQyKM7:TR?= NYCzXo9JOjZ3N{WxOlc>
BEL7402 NFX5SpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrwUpdHOC1zMDFOwG0> NY\PToJ1PSCm M4TXWGROW09? M{TkOWlEPTB;MD60O{DPxE1? Mn\sNlY2PzVzNke=
MHCC97H MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXKNE0yOCEQvF2= MmThOUBl NHLBUnFFVVOR NYPxN2ltUUN3ME2wMlQyKM7:TR?= NF3RVpkzPjV5NUG2Oy=>
Hep3B MmrZR4VtdCCFeXPs[UBCe3OjeR?= NUfuV4JlOC5zL{CuOU8zNjVizszN MoTPOFghcA>? MkX5SG1UVw>? M4Xwd4xm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? NETqZWkzPjV5NUG2Oy=>
HCCLM3 NYDWTZNDS2WubDDDfYNt\SCDc4PhfS=> NEn5XZgxNjFxMD61M|IvPSEQvF2= NWr5R3E5PDhiaB?= MYfEUXNQ M13GTIxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? MmLrNlY2PzVzNke=
Hep3B Mn[3RZBweHSxc3nzJGF{e2G7 NID1PVQxNjFxMD61M|IvPSEQvF2= NXTE[mFpPDhiaB?= MVTEUXNQ MXLhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli M3naSlI3PTd3MU[3
HCCLM3 NFW3eW9CeG:ydH;zbZMhSXO|YYm= NYnwR2hrOC5zL{CuOU8zNjVizszN NUTBdXF{PDhiaB?= MV;EUXNQ MljVZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? MX[yOlU4PTF4Nx?=
A549 NIr4XWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6wMlEuOTBizszN NGK2doQ4OiCq NYPQUZVVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NHqweYgzPjRzNUKyOS=>
H157 NYfVeXc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXHR2cxNjFvMUCg{txO MoTBO|IhcA>? MnT4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXSyOlQyPTJ{NR?=
H1299 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnoZXYxNjFvMUCg{txO MlTSO|IhcA>? M{T1R4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MV:yOlQyPTJ{NR?=
A549 MlH0SpVv[3Srb36gRZN{[Xl? NUj4Z3hlOS9{LkWvOUDPxE1? NV7LWFE{OTJiaB?= NVTDZ3FyyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= NHK2[4EzPjRzNUKyOS=>
H1299 MULGeY5kfGmxbjDBd5NigQ>? MlK5NU8zNjVxNTFOwG0> MkO3NVIhcA>? NXfRNHJFyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= MWCyOlQyPTJ{NR?=
H157 MWTGeY5kfGmxbjDBd5NigQ>? MUOxM|IvPS93IN88US=> MUWxNkBp NXjSfpRm\GWlcnXhd4VlKESUNDDlfJBz\XO|aX;u Ml;GNlY1OTV{MkW=
H1299 MlK4SpVv[3Srb36gRZN{[Xl? Mo[0NU8zNjVxNTFOwG0> Ml;xNVIhcA>? NH7RfYdl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= NFTRXY0zPjRzNUKyOS=>
C8161 MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NU\G[HN2OC1{IN88US=> Mnq1OEBl MlPESG1UVw>? MmP6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkHONlY{QTd{MkO=
Mel285 NEn1O|lE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWjNbYZJOC1{IN88US=> NF7OTpM1KGR? MnLySG1UVw>? MV3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnHkNlY{QTd{MkO=
Mel290 NXriZ3J7S2WubDDWbYFjcWyrdImgRZN{[Xl? NUHk[|U{OC1{IN88US=> MYe0JIQ> MV\EUXNQ M{\uNIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Ml\ENlY{QTd{MkO=
92.1 MnP0R4VtdCCYaXHibYxqfHliQYPzZZk> MYiwMVIh|ryP NXLKSJF4PCCm MVfEUXNQ MV;k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1HxeVI3Ozl5MkKz
Omm1.3 NIHMdZJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV2wMVIh|ryP MWi0JIQ> M{PWTGROW09? M{LDU4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoHNNlY{QTd{MkO=
Mel202 M2G3N2NmdGxiVnnhZoltcXS7IFHzd4F6 M3;jSlAuOiEQvF2= NHf0dXo1KGR? M{PtWmROW09? NIXVWXBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2i1N|I3Ozl5MkKz
Mel270 M{f2[GNmdGxiVnnhZoltcXS7IFHzd4F6 NHj1dFExNTJizszN NILkXmo1KGR? MkLOSG1UVw>? MVvk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn\4NlY{QTd{MkO=
Omm1 NH;OTVlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGK0[owxNTJizszN MXK0JIQ> M{DTW2ROW09? NILjN4pl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mo\0NlY{QTd{MkO=
92.1 NU\QPYtTSXCxcITvd4l{KEG|c3H5 NXO0[GFUPTByIH7N NVjwU3dnPDhiaB?= NX;UUmpqTE2VTx?= MkO4bY5lfWOnczDhdI9xfG:|aYO= MoHRNlY{QTd{MkO=
Omm1.3 MnTpRZBweHSxc3nzJGF{e2G7 NHv3dWM2ODBibl2= MkPxOFghcA>? MXPEUXNQ NGfM[ohqdmS3Y3XzJIFxd3C2b4Ppdy=> NYf2WFFMOjZ|OUeyNlM>
92.1 NVLUc|JnS2WubDDDfYNt\SCDc4PhfS=> M124flUxOCCwTR?= M1j6R|I1NzR6L{eyJIg> M1;1RWROW09? NIjt[IRqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= MkXQNlY{QTd{MkO=
Omm1.3 M{\2NmNmdGxiQ4njcIUhSXO|YYm= MYG1NFAhdk1? MlPSNlQwPDhxN{KgbC=> MnrzSG1UVw>? NHfoWFBqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= NITkO|gzPjN7N{KyNy=>
A549 M3juS2Z2dmO2aX;uJGF{e2G7 NVTV[3lDOTByL{SwNE8yODByIH7N NHn1XIUzPCCq M37vZpVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? MnLrNlYzOTJzOUm=
MCF-7 NHrRfFlHfW6ldHnvckBCe3OjeR?= M3vuW|ExOC92MECvNVAxOCCwTR?= MVOyOEBp M1raOZVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? M2HDfVI3OjF{MUm5
HEK293 NV7VXGJvTnWwY4Tpc44hSXO|YYm= NVT4Rml1OTByL{SwNE8yODByIH7N NUPWWIdyOjRiaB?= M3jRdZVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? NXy5OYl[OjZ{MUKxPVk>
858 NXnPdG53S2WubDDWbYFjcWyrdImgRZN{[Xl? MnfuNE0yKM7:TR?= NG\KZmw2KGR? M1zOb2ROW09? MYTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmPINlYzODZ|M{O=
DDR2L63V Ml7jR4VtdCCYaXHibYxqfHliQYPzZZk> MV2wMVEh|ryP NWPVTI5mPSCm MUXEUXNQ NEnsTFdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{nzZlI3OjB4M{Oz
BE(2)-C MoXER4VtdCCYaXHibYxqfHliQYPzZZk> MlzCNUDPxE1? MnjkNU01KGR? M3\YeIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NV:2[pVrOjZyNke0OlQ>
IMR-32 M1T0cGNmdGxiVnnhZoltcXS7IFHzd4F6 MoHnNUDPxE1? MmHnNU01KGR? MnLU[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NH;2UmwzPjB4N{S2OC=>
JF NInY[ZRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEC2U4syKM7:TR?= M1rSVVEuPCCm NFrFU5pl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MXyyOlA3PzR4NB?=
BE(2)-M17 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlrXNUDPxE1? MmfjNU01KGR? MXTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MXmyOlA3PzR4NB?=
SK-N-SH Mn;RR4VtdCCYaXHibYxqfHliQYPzZZk> NF3FXJoyKM7:TR?= M1HIeFEuPCCm Monv[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NXPMWIdzOjZyNke0OlQ>
SK-N-DZ  M4m4XWNmdGxiVnnhZoltcXS7IFHzd4F6 NEm3UXEyKM7:TR?= M376RlEuPCCm MYnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MX:yOlA3PzR4NB?=
HMC-1.1  MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7l[IlUPS13MECwJI5O Mm\LOFghcA>? MY\EUXNQ M1nDXolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXOyOlA2PTNyMx?=
HMC-1.2 NFq2PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPpTFRqPS13MECwJI5O NVi1bo5zPDhiaB?= NVu0VolJTE2VTx?= MmXhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUTvTmJnOjZyNUWzNFM>
ROSA KIT WT  NEXxXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC1MVUxODBibl2= NH7qbos1QCCq NGX5TldFVVOR NUj5U3czcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mny2NlYxPTV|MEO=
ROSA KIT D816V MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4mxXVUuPTByMDDuUS=> NX\xcW06PDhiaB?= Mn\oSG1UVw>? NWrYRY9kcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NILQRpQzPjB3NUOwNy=>
HMC-1.1  M3rMNWFxd3C2b4Ppd{BCe3OjeR?= NGT5dIozODBvNUCwNEBvVQ>? NWPQd|A2PDhiaB?= Mn3hSG1UVw>? M4PKZYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1fZT|I3ODV3M{Cz
HMC-1.2 M2T6cmFxd3C2b4Ppd{BCe3OjeR?= M{nvWFIxOC13MECwJI5O NYfGcGY5PDhiaB?= MoqzSG1UVw>? MlXtbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3XCO|I3ODV3M{Cz
ROSA KIT WT  NWTVbpN4SXCxcITvd4l{KEG|c3H5 MXqyNFAuPTByMDDuUS=> NG[wVVY1QCCq M2\JR2ROW09? NWLFPI5[cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWDZUnNPOjZyNUWzNFM>
ROSA KIT D816V M2XvbWFxd3C2b4Ppd{BCe3OjeR?= NXPuNHlPOjByLUWwNFAhdk1? MVS0PEBp MnK4SG1UVw>? MlHSbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3ftc|I3ODV3M{Cz
494H MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jsSFczKGh? Ml7XSG1UVw>? M4X3U2lEPTB;MD6xNlLDuTBwMEC0JO69VQ>? Mny3NlU6PDR3Nk[=
493H MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHVfZU4OiCq MmDBSG1UVw>? M4fKZmlEPTB;MD6wOFfDuTBwMEC5JO69VQ>? M3vuO|I2QTR2NU[2
716H NGD5SWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj3Ook4OiCq MV;EUXNQ NXHnflhyUUN3ME2wMlIyOsLzMD6wN|Qh|ryP NULGUIVQOjV7NES1OlY>
148I MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnPTJg4OiCq NYfGeldYTE2VTx?= NHP2e4JKSzVyPUCuNlg1yrFyLkCzOUDPxE1? MlyyNlU6PDR3Nk[=
98Sc MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HMWFczKGh? NYS3ZWVQTE2VTx?= M3zMVWlEPTB;MD6xNVXDuTBwMEC0JO69VQ>? NH35boQzPTl2NEW2Oi=>
89R M{DJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXDO|IhcA>? M2XacGROW09? Ml7KTWM2OD1yLkGyOuKyOC5yMEOg{txO MYqyOVk1PDV4Nh?=
494L NWHGXoNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe3NkBp Ml7lSG1UVw>? NVfLZo5zUUN3ME2wMlMyP8LzMD6wNVIh|ryP NIPlSG4zPTl2NEW2Oi=>
493L M1O3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGftbGg4OiCq MYLEUXNQ NYfRTHoxUUN3ME2wMlA2OMLzMD6wNVEh|ryP M1rQUFI2QTR2NU[2
148L M4eze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH2c5c4OiCq NFvMVmJFVVOR NUHCUlRFUUN3ME2wMlE1PsLzMD6wNVch|ryP M2i1ZlI2QTR2NU[2
98L MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXyO|IhcA>? NVvOSGg6TE2VTx?= MoXpTWM2OD1yLkOwPeKyOC5yMkmg{txO NWLQXoRjOjV7NES1OlY>
OS17 NInrUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XUcVczKGh? NWjYeWpqTE2VTx?= NXK3cXZLUUN3ME2wMlA4QcLzMD6wNFMh|ryP NUfIWVNQOjV7NES1OlY>
OS9 Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\DO|IhcA>? MlfDSG1UVw>? M17mSGlEPTB;MD60NFbDuTBwMEK4JO69VQ>? M3fhflI2QTR2NU[2
MG63 M2\HPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjhSGM4OiCq M1rxV2ROW09? NEDiTYpKSzVyPUCuNVE1yrFyLkCyOUDPxE1? NHnzU4ozPTl2NEW2Oi=>
SAOS2 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rjcVczKGh? NFSxcJNFVVOR MYLJR|UxRTBwMkG3xtExNjByMzFOwG0> M3jQNVI2QTR2NU[2
U2OS MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHyXXU4OiCq M4jsUWROW09? MljpTWM2OD1yLkG5POKyOC5yMEig{txO MoPoNlU6PDR3Nk[=
SJSA-1 Mn\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ROVczKGh? M{i4TWROW09? NEPUfJFKSzVyPUCuNVAxyrFyLkCxNEDPxE1? MV:yOVk1PDV4Nh?=
494H M{i0VmFxd3C2b4Ppd{BCe3OjeR?= M1nXPFAvOjVxMD61M|EvOCEQvF2= NHe2dWczPCCq M1zOdWROW09? NGHmfXlqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? MV2yOVk1PDV4Nh?=
148I NWLFNIk{SXCxcITvd4l{KEG|c3H5 MmDXNE4zPS9yLkWvNU4xKM7:TR?= Mn;iNlQhcA>? MYnEUXNQ M1LHfIlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? Ml2xNlU6PDR3Nk[=
OS17 NWWyTJl3SXCxcITvd4l{KEG|c3H5 M{GwUFAvOjVxMD61M|EvOCEQvF2= M4P1ZlI1KGh? MoLTSG1UVw>? MX7pcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MUmyOVk1PDV4Nh?=
494H M4PZXmFxd3C2b4Ppd{BCe3OjeR?= MVmx5qCK|ryP MlTJOFghcA>? NIOy[IJFVVOR M4HXUIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> MYCyOVk1PDV4Nh?=
148I MVHBdI9xfG:|aYOgRZN{[Xl? M12zXlHjiIoQvF2= M1vIelQ5KGh? MoK4SG1UVw>? NYrSZVhycW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MnPONlU6PDR3Nk[=
OS17 Mnm1RZBweHSxc3nzJGF{e2G7 MnnUNgKBkc7:TR?= M3WzbFQ5KGh? NULncow6TE2VTx?= MYfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= M4PzV|I2QTR2NU[2
MOLM13 MkLIRZBweHSxc3nzJGF{e2G7 MVGyOVAhdk1? M4X2eVQ5KGh? MnHHSG1UVw>? MWLpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? NVHpUHBSOjVyNUO4NlU>
MV4-11  NXPZTVR2SXCxcITvd4l{KEG|c3H5 NFXXZXQzPTBibl2= MVy0PEBp M1PmZmROW09? NEnuc2ZqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= NV\1Wpk6OjVyNUO4NlU>
MOLM13 MmflSpVv[3Srb36gRZN{[Xl? MWKyOVAhdk1? MmDwNlQhcA>? NHHsco9FVVOR M3XVWIVvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= MUKyOVA2Ozh{NR?=
MV4-11  NXLqbVRyTnWwY4Tpc44hSXO|YYm= M2DjT|I2OCCwTR?= M3m1WlI1KGh? M2rBeWROW09? NHjoSJBmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC= NFzPPGUzPTB3M{iyOS=>
MOLM13 NY\WfWo5SXCxcITvd4l{KEG|c3H5 NIHlT4EzPTBibl2= NIDqSoo1QCCq M1rBXmROW09? MULpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheG:wYYTpcolj NWPncI01OjVyNUO4NlU>
MV4-11  Ml\mRZBweHSxc3nzJGF{e2G7 NVjJdHpZOjVyIH7N NYLoUndUPDhiaB?= NXO1fGx2TE2VTx?= M4\hOIlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? NEm0SlMzPTB3M{iyOS=>
Hela NGGwTZhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF34cW8xNTVyMDDuUS=> NITuOnY4OiCq MlLmSG1UVw>? M3HveoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGrwVZczPTByOUK5OS=>
HBL-1 MlTNR4VtdCCYaXHibYxqfHliQYPzZZk> MXywMVUxOCCwTR?= MYC3NkBp MYHEUXNQ M1TreIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFfnflQzPTByOUK5OS=>
HLY-1 NHzqeHJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mn:2NE02ODBibl2= MVi3NkBp NEjUTIJFVVOR NUnKelZr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYKyOVAxQTJ7NR?=
OCI-Ly3 NHPwRndE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWDYUnJoOC13MECgcm0> NH;TSJA4OiCq M1LLOGROW09? NEPaTnBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mn3pNlUxODl{OUW=
OCI-Ly10 M4HhU2NmdGxiVnnhZoltcXS7IFHzd4F6 NYe5T|g2OC13MECgcm0> M3jGW|czKGh? M4\XRmROW09? NILvTFll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MkDrNlUxODl{OUW=
SU-DHL-4 NEnxdFdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoD2NE02ODBibl2= MWm3NkBp MnztSG1UVw>? Mkfl[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUL4[W1QOjVyMEmyPVU>
SU-DHL-5 MmD4R4VtdCCYaXHibYxqfHliQYPzZZk> NGjCOnUxNTVyMDDuUS=> NWHN[HI2PzJiaB?= NFjMPY1FVVOR NWrCNYtj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHTpclAzPTByOUK5OS=>
SU-DHL-6 M4q5cmNmdGxiVnnhZoltcXS7IFHzd4F6 MUCwMVUxOCCwTR?= NYfKTIRYPzJiaB?= MWLEUXNQ MlXv[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGm0PZczPTByOUK5OS=>
SU-DHL-10 M4nyPGNmdGxiVnnhZoltcXS7IFHzd4F6 M1TMS|AuPTByIH7N M{n3NFczKGh? NVfwXGl4TE2VTx?= Mlj4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHPOSZkzPTByOUK5OS=>
RC-K8 M{P4VGNmdGxiVnnhZoltcXS7IFHzd4F6 NXjESIFrOC13MECgcm0> M{W0W|czKGh? M3:3RmROW09? NFW3XZll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MX:yOVAxQTJ7NR?=
OCI-Ly8 NEToUpJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3z1XlAuPTByIH7N MnqzO|IhcA>? MVPEUXNQ NHzsU3Bl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmPtNlUxODl{OUW=
OCL-Ly18 NVntbpB2S2WubDDWbYFjcWyrdImgRZN{[Xl? MWqwMVUxOCCwTR?= MXe3NkBp M3\WT2ROW09? M3flPIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MV6yOVAxQTJ7NR?=
OCI-Ly3 NF35Nm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2xO|IwOjVyL{WwNEBvVQ>? NFvDNY0zNzdiZB?= MoDYSG1UVw>? Mn\3bY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= NH\4PIczPTByOUK5OS=>
OCI-Ly8 NF3mSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu5bWVpOTd{L{K1NE82ODBibl2= MnjZNk84KGR? MljMSG1UVw>? Ml7NbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= NGf1NHEzPTByOUK5OS=>
SU-DHL-4 M2TYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LGZVE4Oi9{NUCvOVAxKG6P MYGyM|ch\A>? NXTPNVNwTE2VTx?= MWTpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi MXeyOVAxQTJ7NR?=
SU-DHL-10 NH74[lhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xO|IwOjVyL{WwNEBvVQ>? NU\lb25OOi95IHS= NEi4XYdFVVOR M{\SOYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= NFe1TmEzPTByOUK5OS=>
OCI-Ly3 MWjBdI9xfG:|aYOgRZN{[Xl? MVSxO|IwOjVyIH7N MWi3[C=> NEL4coRFVVOR NELNVmRqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> NYnMU4I6OjVyMEmyPVU>
OCI-Ly8 NETPOYhCeG:ydH;zbZMhSXO|YYm= NHHPcm8yPzJxMkWwJI5O NUTkUnZSP2R? Mof6SG1UVw>? NFfCRVZqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> M1fWTlI2ODB7Mkm1
SU-DHL-4 MXzBdI9xfG:|aYOgRZN{[Xl? NVG0dG8zOTd{L{K1NEBvVQ>? MV:3[C=> M1;DXWROW09? NWLjOGVIcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NX:1U5ptOjVyMEmyPVU>
SU-DHL-10 MWXBdI9xfG:|aYOgRZN{[Xl? MkjONVczNzJ3MDDuUS=> NIfiV|c4\A>? M1flNGROW09? M1nlNYlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> MnnuNlUxODl{OUW=

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID